Asymchem Laboratories (Tianjin) (SHE:002821, HKG:6821) expects an up to 63% fall in 2024 profit amid lower margins and high research and development costs.
The pharmaceutical services provider forecasts an attributable net profit of between 850 million yuan and 1.05 billion yuan for 2024, down from 2.27 billion yuan in 2023, according to a Tuesday filing with the Shenzhen bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments